All In Biotech

Drug Trial Radar · NCT07339267

A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer

A Phase 1, Open-label Study to Evaluate the Pharmacokinetics and Safety of ASP5541 in Chinese Participants With Advanced Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Jan 20, 2026

Primary completion

Oct 31, 2028

Study completion Oct 31, 2028

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Jan 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, ASP5541 will be given to Chinese men with prostate cancer. It will be given together with prednisone and androgen deprivation therapy (ADT). Prednisone is a steroid, and ADT is already given to the men as their standard of care for prostate cancer. The main aims of the study are to check the safety of ASP5541, when given with prednisone and ADT, and to check how ASP5541 moves through the bodies of Chinese men. The men will receive ASP5541 as an injection into a muscle (intramuscular injection) at the side of the hip. They will all receive the same dose of ASP5541. The men will be given prednisone and ADT according to their label. The men will continue to receive ASP5541 with prednisone and ADT until their cancer gets worse or the doctor decides the men should stop study treatment.

Conditions

  • Prostate Cancer
  • Metastatic Castration-Resistant Prostate Cancer
  • Metastatic Hormone Sensitive Prostate Cancer

Interventions

  • ASP5541Drug

    Intramuscular injection

  • PrednisoneDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK) of Abiraterone Decanoate in Plasma: Maximum Concentration (Cmax)Time frame: Up to 6 months
  2. PK of Abiraterone Decanoate in Plasma: Time to Maximum Concentration (Tmax)Time frame: Up to 6 months
  3. PK of Abiraterone Decanoate in Plasma: Area Under the Curve from Time 0 to the Time of the Last Measurable Concentration (AUClast)Time frame: Up to 6 months
  4. PK of Abiraterone Decanoate in Plasma: Area Under the Concentration Time Curve from the Time of Dose Extrapolated to Time Infinity (AUCinf)Time frame: Up to 6 months
  5. PK of Abiraterone in Plasma: Maximum Concentration (Cmax)Time frame: Up to 6 months
  6. PK of Abiraterone in Plasma: Time to Maximum Concentration (Tmax)Time frame: Up to 6 months
  7. PK of Abiraterone in Plasma: Area Under the Curve from Time 0 to the Time of the Last Measurable Concentration (AUClast)Time frame: Up to 6 months
  8. PK of Abiraterone in Plasma: Area Under the Concentration Time Curve from the Time of Dose Extrapolated to Time Infinity (AUCinf)Time frame: Up to 6 months
  9. Number of Participants with Adverse Events (AEs)Time frame: Up to 33 months
  10. Number of Participants with Laboratory Value Abnormalities and/or AEsTime frame: Up to 31 months
  11. Number of Participants with Electrocardiogram (ECG) Abnormalities and/or AEsTime frame: Up to 31 months
  12. Number of Participants with Vital Sign Abnormalities and/or AEsTime frame: Up to 31 months
  13. Number of Participants with Physical Exam Abnormalities and/or AEsTime frame: Up to 31 months
  14. Number of Participants at Each Grade of Eastern Cooperative Oncology Group (ECOG) Performance Status ScoreTime frame: Up to 31 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.